Embecta Corp. $EMBC Shares Purchased by Meros Investment Management LP

Key Points

• Meros Investment Management LP increased its stake in Embecta Corp. by 37.2%, owning a total of 339,406 shares valued at approximately $4.3 million.
• Embecta reported $1.12 earnings per share, exceeding analysts' estimates and marking an 8.4% year-on-year revenue growth.
• The company declared a quarterly dividend of $0.15, representing an annual yield of 4.4%, with payment scheduled for September 15th.

Meros Investment Management LP increased its holdings in Embecta Corp. (NASDAQ:EMBC - Free Report) by 37.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 339,406 shares of the company's stock after purchasing an additional 92,094 shares during the period. Embecta accounts for 2.5% of Meros Investment Management LP's investment portfolio, making the stock its 16th biggest position. Meros Investment Management LP owned about 0.58% of Embecta worth $4,327,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in EMBC. Sterling Capital Management LLC raised its holdings in Embecta by 796.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,685 shares of the company's stock valued at $35,000 after buying an additional 1,497 shares during the period. Wealthquest Corp acquired a new position in shares of Embecta during the first quarter worth about $48,000. Picton Mahoney Asset Management acquired a new position in shares of Embecta during the first quarter worth about $50,000. Ameriflex Group Inc. acquired a new position in shares of Embecta during the fourth quarter worth about $53,000. Finally, Siemens Fonds Invest GmbH acquired a new position in shares of Embecta in the fourth quarter worth about $77,000. Hedge funds and other institutional investors own 93.83% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. BTIG Research set a $25.00 price target on Embecta and gave the stock a "buy" rating in a research note on Friday, May 23rd. Wall Street Zen raised Embecta from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Finally, Mizuho decreased their price objective on Embecta from $13.00 to $12.00 and set a "neutral" rating for the company in a report on Wednesday, July 16th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Embecta has an average rating of "Hold" and a consensus price target of $19.00.

Insider Activity at Embecta

In other Embecta news, Director David F. Melcher bought 10,000 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were acquired at an average cost of $10.60 per share, with a total value of $106,000.00. Following the acquisition, the director directly owned 86,681 shares of the company's stock, valued at $918,818.60. The trade was a 13.04% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.42% of the stock is owned by insiders.

Embecta Stock Up 0.5%

Embecta stock traded up $0.0650 during trading on Thursday, reaching $13.9550. The stock had a trading volume of 165,863 shares, compared to its average volume of 603,504. Embecta Corp. has a 52-week low of $9.20 and a 52-week high of $21.48. The business has a 50 day moving average price of $10.78 and a 200 day moving average price of $12.10. The stock has a market cap of $816.23 million, a PE ratio of 9.76, a P/E/G ratio of 0.76 and a beta of 1.08.

Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.77 by $0.35. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The company had revenue of $295.50 million for the quarter, compared to analysts' expectations of $278.15 million. During the same quarter last year, the company earned $0.74 earnings per share. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. On average, equities analysts predict that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 29th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Friday, August 29th. Embecta's payout ratio is presently 41.96%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.